A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
NCT ID: NCT00666900
Last Updated: 2012-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
366 participants
INTERVENTIONAL
2008-01-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
NCT01194375
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris
NCT03170388
A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
NCT00663286
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
NCT03003247
A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
NCT00664248
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Low Strength IDP-107
Once a day for 12 weeks
2
High Strength IDP-107
Once a day for 12 weeks
3
Placebo Comparator
Once a day for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low Strength IDP-107
Once a day for 12 weeks
High Strength IDP-107
Once a day for 12 weeks
Placebo Comparator
Once a day for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dow Pharmaceutical Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States
Dermatology Research of Arkansas, PLLC
Little Rock, Arkansas, United States
RADY Children's Hospital - San Diego
San Diego, California, United States
Clinical Science Institute
Santa Monica, California, United States
Solano Clinical Research
Vallejo, California, United States
Cherry Creek Research, Inc.
Denver, Colorado, United States
FXM Research Corp.
Miami, Florida, United States
Michigan Center for Skin Care Research
Clinton Township, Michigan, United States
Hamzavi Dermatology
Fort Gratiot, Michigan, United States
Minnesota Clinical Study Center
Fridley, Minnesota, United States
Skin Specialist, PC
Omaha, Nebraska, United States
Academic Dermatology Associates
Albuquerque, New Mexico, United States
Dermatology Associates of Rochester
Rochester, New York, United States
DermResearchCenter of New York, Inc.
Stony Brook, New York, United States
University of North Carolina Hospitals and School of Medicine
Chapel Hill, North Carolina, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Oregon Dermatology and Research Center
Portland, Oregon, United States
Arlington Research Center, Inc.
Arlington, Texas, United States
DermResearch, Inc.
Austin, Texas, United States
J & S Studies, Inc.
Bryan, Texas, United States
The Center for Skin Research
Houston, Texas, United States
South Valley Dermatology
West Jordan, Utah, United States
Virginia Clinical Research, Inc.
Norfolk, Virginia, United States
Premier Clinical Research
Spokane, Washington, United States
Madison Skin & Research, Inc.
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DPSI-IDP-107-P2-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.